In this article, some mistakes have been found. The use of MMAS-8 scales required permission from the copyright owner but was missing, and corresponding data were recalculated using the scoring algorithm of MMAS-8. In agreement with the copyright owner of MMAS-8, the following corrections need to be made to this article.
In the section of “The main outcomes”, the scoring of the MMAS-8 scale was incorrectly described. The correct description should read “The Morisky Medication Adherence Scale-8 (MMAS-8) was used to evaluate patients’ treatment compliance, with a total score of 8. The MMAS-8 diagnostic adherence assessment instrument has a range of 0 to 8. Low adherence is 0 to <6, moderate adherence is from 6 to <8 and high adherence is 8”.
The reference for MMAS-8 (original reference [13]) was incorrect. The correct 3 citations for the actual scoring of the MMAS-8 scale are as follows:
[1] Morisky DE, Ang A, Krousel-Wood M and Ward H. Predictive validity of medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10: 348-354.
[2] Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE and Whittle J; SPRINT Research Group. Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med 2017; 377: 733-744.
[3] Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negrón N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS and Moran AE; SPRINT Research Group. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med 2017; 377: 745-755.
The MMAS-8 scores in Figure 2 were recalculated, and the required footnote was included. The correct description should be “After intervention, the scores of MMAS-8 in the observation group (7.20±0.53) were significantly higher than those in the control group (5.02±0.75) (P<0.05), as shown in Figure 2”.
Figure 2.
Comparison of MMAS-8 scores between the two groups of patients after intervention. The MMAS-8 scale, content, name, and trademarks are protected by US copyright and trademark laws. Permission for use of the scale and its coding is required. A license agreement is available from MMAR, LLC., Donald E. Morisky, ScD, ScM, MSPH, 294 Lindura Ct., USA; donald.morisky@moriskyscale.com. MMAS: Morisky Medication Adherence Scale. #P<0.05.